Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Since the start of this week\u0026#39;s trading, the EUR/USD pair has been attempting to rebound upwards, with gains reaching ...

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

美国当局认定诺和诺德减肥药已不再处于短缺，因销售平替版减肥药而爆红的远程医疗平台Hims & Hers也确定将停售仿制减肥药，引发股价崩跌22%，已从月初的高点腰斩。 Business Insider报道，Hims & Hers首席财务官Yemi ...

This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

当地时间周五（2月21日），美国食品和药物管理局（FDA）官网显示，诺和诺德公司报告称司美格鲁肽注射液的短缺和停产情况已经解决。 FDA表格显示，用于治疗2型糖尿病的“Ozempic”（诺和泰）和用于体重管理的“Wegovy”（诺和盈）已经不再供不应求，这类热门药物的短缺情况最早始于2022年8月23日。 FDA称，诺和诺德现在可以在美国全国范围内满足患者的药物需求。这一决定意味着，复方药店将被禁 ...

Super Micro stock slumps with the server maker having until Tuesday to file delayed financial accounts or risk being delisted ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.